Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
10.1186/1471-2407-14-592
Saved in:
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/181520 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
id |
sg-nus-scholar.10635-181520 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-1815202023-11-01T07:42:40Z Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma Haaland, B Chopra, A Acharyya, S Fay, A.P Lopes, G.L DUKE-NUS MEDICAL SCHOOL bevacizumab interferon pazopanib sunitinib angiogenesis inhibitor antineoplastic agent bevacizumab indole derivative interferon monoclonal antibody pazopanib pyrimidine derivative pyrrole derivative sulfonamide sunitinib anemia anorexia Article asthenia cancer risk comparative study diarrhea drug efficacy drug safety drug withdrawal dyspnea fatigue fever headache human hypertension kidney carcinoma loss of appetite metastatic clear cell renal cell carcinoma metastatic clear cell renal cell carcinoma nausea neutropenia overall survival progression free survival proteinuria randomized controlled trial (topic) side effect systematic review thrombocytopenia thyroid disease treatment outcome treatment response Carcinoma, Renal Cell Kidney Neoplasms meta analysis molecularly targeted therapy Neoplasm Metastasis survival Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Humans Indoles Interferons Kidney Neoplasms Molecular Targeted Therapy Neoplasm Metastasis Pyrimidines Pyrroles Randomized Controlled Trials as Topic Sulfonamides Survival Analysis 10.1186/1471-2407-14-592 BMC Cancer 14 1 592 2020-10-27T11:11:13Z 2020-10-27T11:11:13Z 2014 Article Haaland, B, Chopra, A, Acharyya, S, Fay, A.P, Lopes, G.L (2014). Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC Cancer 14 (1) : 592. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2407-14-592 14712407 https://scholarbank.nus.edu.sg/handle/10635/181520 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031 |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
topic |
bevacizumab interferon pazopanib sunitinib angiogenesis inhibitor antineoplastic agent bevacizumab indole derivative interferon monoclonal antibody pazopanib pyrimidine derivative pyrrole derivative sulfonamide sunitinib anemia anorexia Article asthenia cancer risk comparative study diarrhea drug efficacy drug safety drug withdrawal dyspnea fatigue fever headache human hypertension kidney carcinoma loss of appetite metastatic clear cell renal cell carcinoma metastatic clear cell renal cell carcinoma nausea neutropenia overall survival progression free survival proteinuria randomized controlled trial (topic) side effect systematic review thrombocytopenia thyroid disease treatment outcome treatment response Carcinoma, Renal Cell Kidney Neoplasms meta analysis molecularly targeted therapy Neoplasm Metastasis survival Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Humans Indoles Interferons Kidney Neoplasms Molecular Targeted Therapy Neoplasm Metastasis Pyrimidines Pyrroles Randomized Controlled Trials as Topic Sulfonamides Survival Analysis |
spellingShingle |
bevacizumab interferon pazopanib sunitinib angiogenesis inhibitor antineoplastic agent bevacizumab indole derivative interferon monoclonal antibody pazopanib pyrimidine derivative pyrrole derivative sulfonamide sunitinib anemia anorexia Article asthenia cancer risk comparative study diarrhea drug efficacy drug safety drug withdrawal dyspnea fatigue fever headache human hypertension kidney carcinoma loss of appetite metastatic clear cell renal cell carcinoma metastatic clear cell renal cell carcinoma nausea neutropenia overall survival progression free survival proteinuria randomized controlled trial (topic) side effect systematic review thrombocytopenia thyroid disease treatment outcome treatment response Carcinoma, Renal Cell Kidney Neoplasms meta analysis molecularly targeted therapy Neoplasm Metastasis survival Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Humans Indoles Interferons Kidney Neoplasms Molecular Targeted Therapy Neoplasm Metastasis Pyrimidines Pyrroles Randomized Controlled Trials as Topic Sulfonamides Survival Analysis Haaland, B Chopra, A Acharyya, S Fay, A.P Lopes, G.L Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
description |
10.1186/1471-2407-14-592 |
author2 |
DUKE-NUS MEDICAL SCHOOL |
author_facet |
DUKE-NUS MEDICAL SCHOOL Haaland, B Chopra, A Acharyya, S Fay, A.P Lopes, G.L |
format |
Article |
author |
Haaland, B Chopra, A Acharyya, S Fay, A.P Lopes, G.L |
author_sort |
Haaland, B |
title |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
title_short |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
title_full |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
title_fullStr |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
title_full_unstemmed |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
title_sort |
comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma |
publishDate |
2020 |
url |
https://scholarbank.nus.edu.sg/handle/10635/181520 |
_version_ |
1781792535233953792 |